Overview of Dr. Sweet
Dr. Kendra Sweet is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. She received her medical degree from Virginia Commonwealth University School of Medicine and has been in practice 10 years. Dr. Sweet accepts several types of health insurance, listed below. She is one of 172 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 52 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
12902 Magnolia Dr
Tampa, FL 33612- Is this information wrong?
Education & Training
University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 2007 - 2010
Virginia Commonwealth University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2010 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.Lisa Nodzon, Amanda Rodriguez, Akriti G Jain, Quinto Gesiotto, Somedeb Ball, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A Sallman, Jeffrey E Lanc...> ;Annals of Hematology. 2024 Apr 18
- Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seon...> ;Blood Advances. 2024 Mar 12
- 2 citationsPivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.Naval G Daver, Pau Montesinos, Daniel J DeAngelo, Eunice S Wang, Nikolaos Papadantonakis, Elisabetta Todisco, Kendra L Sweet, Naveen Pemmaraju, Andrew A Lane, Laura To...> ;The Lancet. Oncology. 2024 Mar 1
- Join now to see all
Journal Articles
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseKendra Sweet, Fadi Kayali, Javier Pinilla-Ibarz, Leukemia Research
Abstracts/Posters
- Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and VenetoclaxKendra L. Sweet, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...Kendra L. Sweet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- A Phase I Clinical Trial of Ruxolitinib in Combination with Nilotinib in Chronic Myeloid Leukemia Patients with Molecular Evidence of DiseaseOctober 2018
- State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017
Press Mentions
Leukemia Patients Consider Stopping Drug to See if They’re CuredDecember 12th, 2019
Hospital Affiliations
H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
James A. Haley Veterans' Hospital-TampaTampa, Florida
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPOCoventry Florida - Employer Group PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
